About Us

Revive Therapeutics Ltd. is a publicly-traded company listed on the OTCQB: RVVTF in the U.S. and the TSX Venture: RVV in Canada.


Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.


Also, Revive is advancing developments in rare diseases such as, Cystinuria, which was granted FDA Orphan Drug Status, Wilson's disease and Rett syndrome (partnered with Rettsyndrome.org).

Read more



April 19, 2016

Revive Therapeutics Appoints Tessio Rebello, Ph.D. as Clinical Advisor

Read more
February 26, 2016

Revive Therapeutics Ltd Announces Results for the Three and Six Months Ended December 31, 2015

Read more
January 20, 2016

Revive Therapeutics Announces Issuance of U.S. Patent Related to Bucillamine in the Treatment of Gout

Read more
January 19, 2016

Revive Therapeutics to Present at Noble Capital Markets' Investor Conference

Read more
December 08, 2015

Revive Therapeutics Announces DTC Eligibility of Its Common Shares

Read more
Corporate presentation



April 2016